Dihydrolipoyl transacetylase (E2)
Cofactors used
What it does, reaction by reaction
Pyruvate Oxidation / Link Reaction (Pyruvate Dehydrogenase Complex) Carbohydrate Metabolism · Mitochondrial matrix
Acetyl-lipoamide + CoA-SH → acetyl-CoA + dihydrolipoamide
Converts Acetyl-lipoamide CoA-SH into Acetyl-CoA Dihydrolipoamide
› Notes
E2 transfers the acetyl group to coenzyme A (CoA-SH), creating acetyl-CoA. This is a transesterification reaction; CoA is derived from pantothenate (vitamin B5).
Pyruvate Dehydrogenase Complex (Link Reaction, connecting glycolysis to the TCA cycle) Energy Metabolism & Cellular Respiration · Mitochondrial matrix
Hydroxyethyl-TPP + oxidized lipoamide-E2 → acetyl-dihydrolipoamide-E2 + TPP
Converts Hydroxyethyl-TPP Oxidized lipoamide-E2 into Acetyl-dihydrolipoamide-E2 Thiamine pyrophosphate (TPP)
› Notes
Required cofactors: TPP and lipoic acid/lipoamide. The lipoamide “swinging arm” channels intermediates among active sites.
Acetyl-dihydrolipoamide-E2 + CoA-SH → acetyl-CoA + dihydrolipoamide-E2
Converts Acetyl-dihydrolipoamide-E2 CoA-SH into Acetyl-CoA Dihydrolipoamide-E2
› Notes
Required cofactor: CoA, whose reactive thiol forms the acetyl thioester. Acetyl-CoA formation is part of the overall irreversible, committed entry of pyruvate carbon into oxidative metabolism; acetyl-CoA cannot be converted back to pyruvate in humans.
Showing all 3 reactions.
What accelerates and inhibits it
Regulation is pathway-specific, so each context is listed separately
No regulation recorded for this enzyme in the source documents.
Recent literature
Europe PMC · fetched just now · sorted by publication date
-
1
Engineered probiotics couple photothermal cuproptosis with biomechanical disruption and immune activation.
Zhang X, Liu X, Huang K, Jin B, Ma N, Liu H, Jiang H, Wang X. · 2026-09-21
open access unreviewed -
2
Bioinspired zinc-doped carbon dots protect against polystyrene microplastic-induced spermatogenic dysfunction through Nrf2 activation and cuproptosis suppression.
Li T, Li K, Yang S, Pan H, Cai Z, Hua X, Liao G, Luo B, Zhang J. · 2026-09-15
open access unreviewed -
3
Hepatocyte SLC31A1-dependent copper accumulation contributes to hepatic glucose and lipid metabolic disturbances through AMPKα1 inactivation.
Cheng YQ, Wei M, Yang L, Zhuang YY, Lu QB. · 2026-09-11
open access unreviewed -
4
Hijacking tumor metabolism via sonocatalysis to orchestrate cuproptosis-pyroptosis coupling for potent antitumor immunity.
Luo R, Dong L, Chen A, Hu J, Wang S, Zhu X, Wang K, Lu J, Yin X, Luo Y, Jiang F, Liu X. · 2026-08-19
unreviewed -
5
Emerging copper-based hollow nanoplatforms for cancer treatment.
Liang S, Li X, Zhang L, Zhu W, Gan S. · 2026-07-11
open access unreviewed -
6
Mitochondria-related pathogenic genes in acute and chronic kidney disease: a Mendelian randomization study.
Wang J, Yuan T, Wei Q, Xie K, Zhang J. · 2026-07-08
open access unreviewed -
7
A biocompatible copper based therapeutic nanoplatform for CD44 specific tumor targeted therapy and potent immune reprogramming.
Fang Y, Tu M, Tu X, Zhang H, Li Y, Xu J. · 2026-06-13
unreviewed -
8
Suppression of LncRNA AC008406.3 sensitizes breast cancer cells to docetaxel via triggering cuproptosis.
Liu C, Liu S, Lu Z, Cao X, Tong X, Sun I, Hao J, Zhang L. · 2026-05-26
open access unreviewed -
9
Cuproptosis in spinal cord injury: emerging mechanisms and immunological relevance.
Li LH, Zhang JQ, Ying XH, Huang Y, Xu CC, Wang XX, He KL, Ma RJ. · 2026-03-25
cited 1× open access unreviewed -
10
The role of copper and cuproptosis in digestive system cancers: novel therapeutic strategies and mechanistic insights.
Xu G, Yao N, Cheng R, Yang L, Han F, Qu J, Li W. · 2026-03-16
cited 1× open access unreviewed
External claims. These come from an index outside this database and are not checked against it. Treat them as leads.